**Background**
Interferon-gamma (IFN-γ) is a critical pro-inflammatory cytokine that plays a pivotal role in innate and adaptive immunity. It is primarily produced by T cells and natural killer (NK) cells, where it regulates the expression of MHC molecules and activates macrophages. While essential for host defense against intracellular pathogens, dysregulated IFN-γ signaling is implicated in various pathological conditions, including chronic inflammation, autoimmune diseases, and certain malignancies. In the context of Anti-Mouse IFN gamma Antibody cancer research, modulating IFN-γ activity has become a key strategy for understanding tumor progression and immune-mediated tissue damage. Therefore, we will introduce a potent neutralizing agent – Anti-Mouse IFN gamma Antibody.
**Definition**
Anti-Mouse IFN gamma Antibody (XMG1.2) is a rat-derived IgG1 kappa antibody inhibitor designed to target and neutralize IFN-γ. According to the Anti-Mouse IFN gamma Antibody description, this antibody is used to block the biological activity of IFN-γ in both in vitro and in vivo experimental settings.
**In Vitro and In Vivo Studies**
The Anti-Mouse IFN gamma Antibody biological activity has been extensively validated across multiple disease models. In vitro, the antibody is suitable for applications including ELISPOT, flow cytometry, and Western blot to monitor IFN-γ levels and signaling. In vivo studies have demonstrated its efficacy in several challenging models. In multiple myeloma mice models, administration of 500 μg (i.p. at days 0, 3, 7, 10, 14, 17) increased serum IgG2b levels, increased the percentage of mice with progressive disease, and elevated both bone marrow and splenic tumor burdens. In paraneoplastic cerebellar degeneration models, 100 μg (i.p. every other day from day 10) protected mice from weight loss and motor performance decline, while preventing T cell-mediated Purkinje cell death and inhibiting T cell accumulation in the cerebellum. Furthermore, in LPS-induced macrophage activation syndrome models, a single i.p. dose of 100 µg/g significantly increased survival rates (70% survival with 7.5 µg/g LPS and 100% survival with 5 µg/g LPS), while increasing fibrinogen levels and decreasing IL-6 and ALT levels. Additionally, the antibody improved engraftment in Bacillus Calmette-Guerin-infected Ifngr1 -/- mice when administered at 100 mg/kg (i.v. after 14, 20, 28, 35, and 42 days). In conclusion, Anti-Mouse IFN gamma Antibody is a powerful tool for neutralizing IFN-γ to study chronic inflammation and cancer.
Keywords
Anti-Mouse IFN gamma Antibody (XMG1.2), IFNAR, Interferon-α/β receptor, Interferon-alpha/beta receptor, IFN-γ, Cancer, Inflammation, Immunology, Multiple myeloma, Chronic inflammation, Purkinje cell, Macrophage, Inhibitor, inhibitor, inhibit
References
[1] Kellermayer Z, et al. Interferon gamma-mediated prevention of tumor progression in a mouse model of multiple myeloma. Hemasphere. 2024 Dec 2;8(12):e70047.
[2] Prencipe, G., et al. Neutralization of Interferon-gamma is efficacious in a mouse model of HLH secondary to chronic inflammation. Pediatr Rheumatol 13 (Suppl 1), O29 (2015).
[3] Merli P, et al. Role of interferon-γ in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation. Haematologica. 2019 Nov;104(11):2314-2323.
[4] Yshii L, et al. IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration. JCI Insight. 2019 Apr 4;4(7):e127001.
[5] Prencipe G, et al. Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J Allergy Clin Immunol. 2018 Apr;141(4):1439-1449.